Market Overview

Biotech Stock Rally Is Crushing Short Sellers

Share:
Biotech Stock Rally Is Crushing Short Sellers

Benzinga’s Take

Biotech stocks are often high-risk, high-reward investments that have binary outcomes based on one or a handful of drug or device candidates in development. Shorting these types of stocks can be very risky due to the potential for unexpected positive testing data, regulatory approvals and buyouts.

Biotech Stock Rally Is Crushing Short Sellers

Biotech short sellers got off to a red-hot start to 2020, but the aggressive rally in biotech stocks has now all but erased what was once a $7.2 billion mark-to-market profit.

As of late last week, S3 Partners analyst Ihor Dusaniwsky reported that that massive 2020 profit was down to just $12 million for biotech short sellers. Dusaniwsky said the biotech sector currently has $49.2 billion in total short interest, and short sellers have covered only $612 million of their biotech positions over the past month.

Here are three most heavily shorted stocks in the biotech sector, according to S3:

  • AbbVie Inc (NYSE: ABBV), $5.95 billion short interest.
  • Gilead Sciences, Inc. (NASDAQ: GILD), $1.83 billion short interest.
  • Amgen, Inc. (NASDAQ: AMGN), $1.71 billion short interest.

Given the relatively small floats of many stocks in the biotech group, the average outstanding short percentage of float among biotechs is relatively high at 11.1%. Here are the three stocks with the highest short percent of float (minimum $50 million in short interest):

  • Ligand Pharmaceuticals Inc. (NASDAQ: LGND), 59.9% of float.
  • Precigen Inc (NASDAQ: PGEN), 50% of float.
  • Madrigal Pharmaceuticals Inc (NASDAQ: MDGL), 39.7% of float.

Short Squeeze Candidates

Dusaniwsky said short sellers are paying an average daily borrow cost of $1.3 million just to keep their positions open. In addition to the fees, short sellers are taking huge hits on a handful of biotech stocks that have skyrocketed in recent weeks.

For example, Moderna Inc (NASDAQ: MRNA), Novavax, Inc. (NASDAQ: NVAX) and Inovio Pharmaceuticals Inc (NASDAQ: INO) short sellers are all down more than 95% year-to-date.

“We will probably see short covering in stocks with over -50% returns over the last month as short sellers trim their exposure in order to cut their losses,” Dusaniwsky said.

Do you agree with this take? Email feedback@benzinga.com with your thoughts.

Related Links:

Short Sellers Bank $279M Profit On Norwegian Bankruptcy Concerns

Airline Stock Short Sellers Have Made A $4B Profit In 2020

Latest Ratings for GILD

DateFirmActionFromTo
Jul 2020Credit SuisseMaintainsNeutral
Jul 2020Morgan StanleyMaintainsEqual-Weight
Jul 2020Credit SuisseUpgradesUnderperformNeutral

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

 

Related Articles (GILD + MRNA)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Penny Stocks Short Sellers Top Stories Analyst Ratings Trading Ideas General Best of Benzinga

Latest Ratings

StockFirmActionPT
MLVFPiper SandlerMaintains15.0
IMMUPiper SandlerMaintains60.0
HUMPiper SandlerMaintains473.0
GMEDPiper SandlerMaintains55.0
FSLYPiper SandlerMaintains88.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com